NCT02155673 - A Phase 2 Extension Study of Study GCS-100-CS-4002 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

June 30, 2016

Conditions

Chronic Kidney Disease

Interventions

DRUG

GCS-100

1.5 mg/m2 or 30 mg/m2 GCS-100. GCS-100 will be administered as IV infusions once weekly for 8 weeks with a 1 week and 4 week follow-up period and then at least every 30 days for up to a total of 1 year.

Trial Locations (5)

28801

Mountain Kidney and Hypertension Associates, PA, Asheville

78215

Clinical Advancement Center, PLLC, San Antonio

80230

Denver Nephrology, Denver

85284

Southwest Clinical Research Institute, LLC, Tempe

91942

California Institute of Renal Research, La Mesa